Endocrine Flashcards

1
Q

Lispro

A

1) Type I DM, Type II DM, gestational DM, life-threatening hyperkalemia, stress-induced hyperglycemia
2) Insulin/Bind insulin receptor (tyrosine kinase activity) -Liver: increase glucose stored as glycogen-Muscle: increase glycogen and protien synthesis and K+ uptake-Fat: aids in TG storage3)Hypoglycemia, very rarely hypersensitivy rxns4)Rapid-acting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Aspart

A

1)Type I DM, Type II DM, gestational DM, life-threatening hyperkalemia, stress-induced hyperglycemia2)Insulin/Bind insulin receptor (tyrosine kinase activity) -Liver: increase glucose stored as glycogen-Muscle: increase glycogen and protien synthesis and K+ uptake-Fat: aids in TG storage3)Hypoglycemia, very rarely hypersensitivy rxns4)Rapid-acting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Glulisine

A

1)Type I DM, Type II DM, gestational DM, life-threatening hyperkalemia, stress-induced hyperglycemia2)Insulin/Bind insulin receptor (tyrosine kinase activity) -Liver: increase glucose stored as glycogen-Muscle: increase glycogen and protien synthesis and K+ uptake-Fat: aids in TG storage3)Hypoglycemia, very rarely hypersensitivy rxns4)Rapid-acting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Regular

A

1)Type I DM, Type II DM, gestational DM, life-threatening hyperkalemia, stress-induced hyperglycemia2)Insulin/Bind insulin receptor (tyrosine kinase activity) -Liver: increase glucose stored as glycogen-Muscle: increase glycogen and protien synthesis and K+ uptake-Fat: aids in TG storage3)Hypoglycemia, very rarely hypersensitivy rxns4)Short-acting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

NPH

A

1)Type I DM, Type II DM, gestational DM, life-threatening hyperkalemia, stress-induced hyperglycemia2)Insulin/Bind insulin receptor (tyrosine kinase activity) -Liver: increase glucose stored as glycogen-Muscle: increase glycogen and protien synthesis and K+ uptake-Fat: aids in TG storage3)Hypoglycemia, very rarely hypersensitivy rxns4)Intermediate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Glargine

A

1)Type I DM, Type II DM, gestational DM, life-threatening hyperkalemia, stress-induced hyperglycemia2)Insulin/Bind insulin receptor (tyrosine kinase activity) -Liver: increase glucose stored as glycogen-Muscle: increase glycogen and protien synthesis and K+ uptake-Fat: aids in TG storage3)Hypoglycemia, very rarely hypersensitivy rxns4)Long-acting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Detemir

A

1)Type I DM, Type II DM, gestational DM, life-threatening hyperkalemia, stress-induced hyperglycemia2)Insulin/Bind insulin receptor (tyrosine kinase activity) -Liver: increase glucose stored as glycogen-Muscle: increase glycogen and protien synthesis and K+ uptake-Fat: aids in TG storage3)Hypoglycemia, very rarely hypersensitivy rxns4)Long-acting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Metformin

A

1)First-line therapy in Type II DM, can be used in pts w/o islet function2)Biguanide/ Exact MOA unknown –> decreases gluconeogenesis, increases glycolysis, increases peripheral glucose uptake (insulin sensitivity)3)GI upset, lactic acidosis (most serious)4)Contraindicated in renal failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Tolbutamide

A

1)Type II DM –stimulate endogenous insulin release2)Sulfonylureas (1st generation)/Close K+ channel in beta cell membrane so cell depolarizes –> triggers insulin release via Ca2+ influx3)Disulfiram-like effects4)Useless in Type I DM b/c requires some islet cell function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Chlorpropamide

A

1)Type II DM –stimulate endogenous insulin release2)Sulfonylureas (1st generation)/Close K+ channel in beta cell membrane so cell depolarizes –> triggers insulin release via Ca2+ influx3)Disulfiram-like effects4)Useless in Type I DM b/c requires some islet cell function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Glyburide

A

1)Type II DM – stimulates endogenous insulin release2)Sulfonylureas (2nd generation)/Close K+ channel in beta cell membrane so cell depolarizes –> triggers insulin release via Ca2+ influx3)Hypoglycemia4)Useless in Type I DM b/c requires some islet cell funciton

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Glimepiride

A

1)Type II DM – stimulates endogenous insulin release2)Sulfonylureas (2nd generation)/Close K+ channel in beta cell membrane so cell depolarizes –> triggers insulin release via Ca2+ influx3)Hypoglycemia4)Useless in Type I DM b/c requires some islet cell funciton

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Glipizide

A

1)Type II DM – stimulates endogenous insulin release2)Sulfonylureas (2nd generation)/Close K+ channel in beta cell membrane so cell depolarizes –> triggers insulin release via Ca2+ influx3)Hypoglycemia4)Useless in Type I DM b/c requires some islet cell funciton

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Pioglitazone

A

1)Monotherapy in Type II DM or in combination therapy2)Glitazone/Thiazolidinedione: Incraeses insulin sensitivity in peripheral tissue; binds PPAR-gamma nuclear transcription regulator –> incr Adiponectin expression3)Weight gain, edema, hepatoxicity, heart failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Rosiglitazone

A

1)Monotherapy in Type II DM or in combination therapy2)Glitazone/Thiazolidinedione: Incraeses insulin sensitivity in peripheral tissue;, binds PPAR-gamma nuclear transcription regulator –> incr Adiponecti expression3)Weight gain, edema, hepatoxicity, heart failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Acarbose

A

1)Monotherapy in Type II DM, or in combination therapy2)Alpha-glucosidase Inhibitor/ Inhibits intestinal brush-border alpha-glucosidases –> get delayed sugar hydrolysis and glucose absorption -decreases postprandial hyperglycemia3)GI disturbances

17
Q

Miglitol

A

1)Monotherapy in Type II DM, or in combination therapy2)Alpha-glucosidase Inhibitor/ Inhibits intestinal brush-border alpha-glucosidases –> get delayed sugar hydrolysis and glucose absorption -decreases postprandial hyperglycemia3)GI disturbances

18
Q

Pramlinitide

A

1)Type I and II DM2)Amylin Analog/ Decreases glucagon3)Hypoglycemia, nausea, diarrhea

19
Q

Exenatide

A

1)Type II DM2)GLP-1 Analog/ Increase insulin and decrease glucagon release3)Nausea, vomiting, pancreatitis

20
Q

Liraglutide

A

1)Type II DM2)GLP-1 Analog/ Increase insulin and decrease glucagon release3)Nausea, vomiting, pancreatitis

21
Q

Linagliptin

A

1)Type II DM2)DPP-4 Inhibitors/ Increase insulin and decrease glucagon release3)Mild urinary or respiratory infections

22
Q

Saxagliptin

A

1)Type II DM2)DPP-4 Inhibitors/ Increase insulin and decrease glucagon release3)Mild urinary or respiratory infections

23
Q

Sitagliptin

A

1)Type II DM2)DPP-4 Inhibitors/ Increase insulin and decrease glucagon release3)Mild urinary or respiratory infections

24
Q

Propylthiouracil

A

1)Hyperthyroidism2)Block peroxidase inhibiting organificatoin of iodide anda coupling of thyroid hormone synthesis -also blocks 5’-deiodinase –> decreases peripheral conversion of T4 to T53)Skin rash, agranulocytosis (rare), aplastic anemia, hepatotoxicity

25
Q

Methimazole

A

1)Hyperthyroidism2)Block peroxidase inhibiting organificatoin of iodide anda coupling of thyroid hormone synthesis3)Skin rash, agranulocytosis (rare), aplastic anemia4)Possible teratogen

26
Q

Levothyroxine

A

1)Hypothyroidism, myxedema2)THyroxine replacement3)Tachycardia, heat intolerance, tremors, arrhythmias

27
Q

Triiodothyronine

A

1)Hypothyroidism, myxedema2)THyroxine replacement3)Tachycardia, heat intolerance, tremors, arrhythmias

28
Q

GH

A

1)GH deficiency, Turner’s Syndrome

29
Q

Somatostatin (octretodie)

A

1)Acromegaly, carcinoid, gastrinoma, glucagonoma, espohageal varices

30
Q

Oxytocin

A

1)Stimulate labor, uterine contractions, milk let-down, controls uterine hemorrhage

31
Q

ADH (Desmopressin)

A

1)Central DI

32
Q

Demeclocycline

A

1)SIADH2)Tetracycline/ ADH antagonist3)Nephrogenic DI, photosensitivity, abnormalities of bone and teeth

33
Q

Hydrocortisone

A

1)Addison’s Disease, inflammation, immune suppression, asthma2)Glucocorticoid/Decrease production of leukotrienes and prostaglandins by inhibiting phospholipase A2 and COX-2 expression3)Iatrogenic Cushing’s –> buffalo hump, moon facies, truncal obesity, muscle wasting, thin skin, bruise easily, osteoporosis, adrenocortical atrophy, peptic ulcers, DM (if chronic)4)Can see adrenal insufficiency when drug is stopped abruptly after chronic use

34
Q

Prednisone

A

1)Addison’s Disease, inflammation, immune suppression, asthma2)Glucocorticoid/Decrease production of leukotrienes and prostaglandins by inhibiting phospholipase A2 and COX-2 expression3)Iatrogenic Cushing’s –> buffalo hump, moon facies, truncal obesity, muscle wasting, thin skin, bruise easily, osteoporosis, adrenocortical atrophy, peptic ulcers, DM (if chronic)4)Can see adrenal insufficiency when drug is stopped abruptly after chronic use

35
Q

Triamcinolone

A

1)Addison’s Disease, inflammation, immune suppression, asthma2)Glucocorticoid/Decrease production of leukotrienes and prostaglandins by inhibiting phospholipase A2 and COX-2 expression3)Iatrogenic Cushing’s –> buffalo hump, moon facies, truncal obesity, muscle wasting, thin skin, bruise easily, osteoporosis, adrenocortical atrophy, peptic ulcers, DM (if chronic)4)Can see adrenal insufficiency when drug is stopped abruptly after chronic use

36
Q

Dexamethasone

A

1)Addison’s Disease, inflammation, immune suppression, asthma2)Glucocorticoid/Decrease production of leukotrienes and prostaglandins by inhibiting phospholipase A2 and COX-2 expression3)Iatrogenic Cushing’s –> buffalo hump, moon facies, truncal obesity, muscle wasting, thin skin, bruise easily, osteoporosis, adrenocortical atrophy, peptic ulcers, DM (if chronic)4)Can see adrenal insufficiency when drug is stopped abruptly after chronic use

37
Q

Beclomethasone

A

1)Addison’s Disease, inflammation, immune suppression, asthma2)Glucocorticoid/Decrease production of leukotrienes and prostaglandins by inhibiting phospholipase A2 and COX-2 expression3)Iatrogenic Cushing’s –> buffalo hump, moon facies, truncal obesity, muscle wasting, thin skin, bruise easily, osteoporosis, adrenocortical atrophy, peptic ulcers, DM (if chronic)4)Can see adrenal insufficiency when drug is stopped abruptly after chronic use